|
|
|
Different regions of the brain and spinal cord house different, specialized cells. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from each of these regions of the developing central nervous system (CNS) in virtually unlimited numbers from a single donated tissue. More |
Neuralstem’s technology uniquely enables the creation of stable neural stem cell lines from the human hippocampus, a part of the brain involved in memory and the generation of new neurons. From these cell lines, the company can create practically unlimited amounts of hippocampal neural stem cells. More |
FDA greenlights 28-day dosing, in depressed patients, of NSI-189 which stimulates new neuron growth in the hippocampus, in ongoing clinical trial designed in collaboration with Harvard/Mass General’s Dr. Fava. More
Ground-breaking transplantation into the gray matter of the spine’s cervical region begins last stage of Neuralstem’s ALS Phase I trial. More
Newsweek’s Science Columnist and Science Editor Sharon Begley reports on Neuralstem’s ongoing ALS trial at Emory. More
Principal Investigator Dr. Eva Feldman presents primary and secondary endpoint trial data on the first 12 ALS patients, showing the Neuralstem cellular therapy procedure to be safe. More
View poster presentation here
U.S. Department of Defense awards Neuralstem a contract to develop its human neural stem cell technology for the treatment of cancerous brain tumors. The company is engineering its cells to attack brain cancer in three ways. More
